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OBJECTIVE—Previous work has demonstrated that chronic
administration of the serotonin reuptake inhibitor (SSRI) ﬂuox-
etine augments counterregulatory responses to hypoglycemia in
healthy humans. However, virtually no information exists regard-
ing the effects of ﬂuoxetine on integrated physiological counter-
regulatory responses during hypoglycemia in type 1 diabetes.
Therefore, the speciﬁc aim of this study was to test the hypoth-
esis that 6-week use of the SSRI ﬂuoxetine would amplify
autonomic nervous system (ANS) counterregulatory responses
to hypoglycemia in individuals with type 1 diabetes.
RESEARCH DESIGN AND METHODS—Eighteen type 1 dia-
betic patients (14 men/4 women aged 19–48 years with BMI
25  3 kg/m
2 and A1C 7.0  0.4%) participated in randomized,
double-blind 2-h hyperinsulinemic (9 pmol  kg
1  min
1)-hypogly-
cemic clamp studies before and after 6 weeks of ﬂuoxetine admin-
istration (n  8) or identical placebo (n  10). Glucose kinetics was
determined by 3-tritiated glucose. Muscle sympathetic nerve activity
(MSNA) was determined by microneurography.
RESULTS—Hypoglycemia (2.8  0.1 mmol/l) and insulinemia
(646  52 pmol/l) were similar during all clamp studies. ANS,
neuroendocrine, and metabolic counterregulatory responses re-
mained unchanged in the placebo group. However, ﬂuoxetine
administration signiﬁcantly (P  0.05) increased key ANS (epineph-
rine, norepinephrine, and MSNA), metabolic (endogenous glucose
production and lipolysis), and cardiovascular (systolic blood pres-
sure) counterregulatory responses during hypoglycemia.
CONCLUSIONS—This study has demonstrated that 6-week ad-
ministration of the SSRI ﬂuoxetine can amplify ANS and metabolic
counterregulatory mechanisms during moderate hypoglycemia in
patients with type 1 diabetes. These data also suggest that the use of
ﬂuoxetine may be useful in increasing epinephrine responses during
hypoglycemia in clinical practice. Diabetes 57:3315–3322, 2008
S
elective serotonin reuptake inhibitors (SSRIs) are
effective drugs for the treatment of depressive
disorders associated with reduced serotonergic
function. Serotonergic neurons play an important
role in the regulation of neuroendocrine function carried
out via both sympathoadrenal and hypothalamic-pituitary-
adrenal (HPA) pathways.
Two studies have reported increased hypoglycemia and
loss of awareness to hypoglycemia related to the use of
SSRIs in depressed patients with type 1 diabetes (1,2).
Although SSRIs are potent inhibitors of neuronal serotonin
uptake, they also have the ability to block norepinephrine
transport (3,4). This would be predicted to increase sym-
pathetic outﬂow activity (4–7). Supporting this, previous
studies by a number of investigators have demonstrated
that SSRIs can modulate sympathetic nervous system
activity and increase counterregulation in rats (8).
Two recent studies in healthy humans (9) and conscious
rats (10) have provided further insight into the effects of
SSRIs on counterregulatory physiology during hypoglyce-
mia. Briscoe et al. (9) investigated the effects of 6 weeks
of high-dose ﬂuoxetine administration on physiological
responses to hypoglycemia in a group of healthy, non-
depressed humans. Key sympathetic nervous system (epi-
nephrine, norepinephrine, and muscle sympathetic nerve
activity [MSNA]) and metabolic (glucose production and
lipolysis) counterregulatory mechanisms were signiﬁ-
cantly ampliﬁed by the SSRI. Sanders et al. (10) elegantly
studied the chronic effects of another SSRI (sertraline) in
a conscious rat model. After 20 days’ administration of the
SSRI, epinephrine and glucagon responses were signiﬁ-
cantly increased during hypoglycemia. Additionally, ser-
traline preserved levels of epinephrine during repeated
hypoglycemia, thereby preventing the blunting effects of
antecedent hypoglycemia on subsequent autonomic ner-
vous system (ANS) counterregulatory responses. Taken
together, the above data suggest that seroteonergic trans-
mission may be an important mechanism in upregulating
sympathetic nervous system drive during hypoglycemia in
both rats and healthy humans.
However, the effects of SSRIs on ANS, neuroendocrine,
and metabolic counterregulatory mechanisms during hy-
poglycemia in type 1 diabetes do not appear to have been
studied. To address this question, the speciﬁc aim of this
study was to test the hypothesis that chronic administra-
tion of the commonly used SSRI ﬂuoxetine would result in
an ampliﬁcation of metabolic and ANS counterregulatory
mechanisms during hypoglycemia in nondepressed indi-
viduals with type 1 diabetes. The glucose clamp technique
was used so that insulin and glucose levels could be
controlled in all studies.
RESEARCH DESIGN AND METHODS
Twenty type 1 diabetic patients (15 men/5 women aged 19–48 years with BMI
25  3 kg/m
2, diabetes duration 18  9 years, and A1C 7.0  0.4% [normal
range 4–6.5%]) were studied. The Zung Self-Rating Depression Scale (11,12)
was completed by each subject to rule out symptoms of clinical depression.
None had a history of epilepsy or any major psychiatric illness. None were
taking any psychotropic medication. Each subject had a normal blood count,
plasma electrolytes, and liver and renal function. All gave written informed
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All study patients were asked to avoid any exercise and consume their
usual weight-maintaining diet for 3 days before each experiment. All patients
performed intensive home blood glucose monitoring (i.e., at least four glucose
tests per day) and were asked to avoid hypoglycemia for at least 5 days before
a study. On the day before a study, intermediate or long-acting insulin was
discontinued and replaced by injections of regular insulin before breakfast
and lunch. Each subject was admitted to the Vanderbilt General Clinical
Research Center (GCRC) at 5:00 P.M. on the evening before an experiment. At
this time, two intravenous cannulae were inserted under 1% lidocaine local
anesthesia. One cannula was placed in a retrograde fashion into a vein on the
back of the hand. This hand would be placed in a heated box (55–60°C) during
the study so that arterialized blood could be obtained (13). The other cannula
was placed in the contralateral arm for infusions. Patients then received a
standardized evening meal, and a continuous low-dose infusion of insulin was
started to normalize plasma glucose. The insulin infusion was adjusted
overnight to maintain blood glucose between 4.4 and 7.2 mmol/l.
Hypoglycemia experiments. After an overnight 10-h fast at 0 min, a primed
(18-Ci) continuous infusion (0.18 Ci/min) of high-performance liquid chro-
matography (HPLC)–puriﬁed [3-
3H]glucose (11.5 mCi  mmol
1  l
1; Perkin
Elmer Life Sciences, Boston, MA) was administered via a precalibrated
infusion pump (Harvard Apparatus, South Natick, MA). A period of 90 min was
allowed to elapse followed by a 30-min basal control period and a 120-min
hyperinsulinemic-hypoglycemic experimental period. An insulin infusion so-
lution was prepared with normal saline containing 3% (vol/vol) of the subject’s
own plasma. At time 120 min, a primed constant (9.0 pmol  kg
1  min
1)
infusion of insulin (Human Regular Insulin; Eli Lilly, Indianapolis, IN) was
started and continued until 240 min. The rate of fall of glucose was controlled
(0.06 mmol/min) and the glucose nadir (2.8 mmol/l) was achieved using a
modiﬁcation of the glucose clamp technique (14). During the clamp period,
plasma glucose was measured every 5 min, and a 20% dextrose infusion was
adjusted so that plasma glucose levels were held constant at 2.8  0.1 mmol/l
(15). Potassium chloride (20 mmol/l) was infused during the clamp to reduce
insulin-induced hypokalemia. After completion of the 2-h test period, the
plasma glucose was rapidly restored to euglycemia with 20% dextrose. A
second identical hyperinsulinemic-hypoglycemic clamp was performed after 6
weeks of the study medication.
Study medication. After the initial 1-day clamp study, volunteers were given
a 1-week medication supply of either ﬂuoxetine or placebo for 6 weeks. The
ﬂuoxetine dose was as follows: 20 mg/day during week 1, 40 mg/day during
week 2, 60 mg/day during week 3, and 80 mg/day during weeks 4–6. The study
was carried out in a double-blind fashion with volunteers and investigators
blinded to the treatment group assigned. Stratiﬁed blocked randomization was
performed by the Vanderbilt Investigational Drug Pharmacy. The subjects
were stratiﬁed according to sex because it is known to affect the counterregu-
latory response (16). Randomization was performed within each sex, and
blocks of two were used to ensure an equal number of men and women in the
placebo and ﬂuoxetine treatment groups.
During the 6-week treatment period, volunteers came to the GCRC once a
week for monitoring of compliance and adverse events. Compliance was
determined via a pill count and a blood draw to measure serum ﬂuoxetine
levels. Two subjects (1 man/1 woman) in the ﬂuoxetine group withdrew from
the study because of side effects. The withdrawals occurred early at the 20-mg
dose and were described as feelings of tiredness and nonspeciﬁc malaise. In
the remaining subjects, ﬂuoxetine was very well tolerated, with no reports of
side effects. After taking either placebo or ﬂuoxetine for 6 weeks, subjects
underwent another single-day hypoglycemic clamp study as previously de-
scribed. Thus, 18 subjects (8 ﬂuoxetine/10 placebo) completed both hypogly-
cemia clamp studies. On completion of this second 1-day study, subjects were
tapered off the study medication (placebo or ﬂuoxetine). Those receiving
ﬂuoxetine were given it for 1 week at 40 mg/day and 1 week at 20 mg/day.
Once subjects ﬁnished the medication, they were unblinded as to the
medication they had taken.
Direct measurement of MSNA. MSNA was recorded from the peroneal
nerve at the level of the ﬁbular head and popliteal fossa (17,18). Nerve activity
was recorded on a PC-based Windaq data acquisition system at 1,000 H2Z
channel-1 (DATAQ Instruments, Akron, OH). Five-minute Windaq ﬁles were
analyzed with a MatLab GUIDE interface (to adjust for an individual’s 1.3-s
nerve burst delay from a once-removed R-R interval, automatically detected
by pulse synchronicity, a 2:1 signal:noise ratio, and wave-form shape). Further
criteria for acceptable MSNA recordings were that 1) electrical stimulation
produced muscle twitches but not paresthesia, 2) nerve activity increased
during phase II of the Valsalva maneuver (hypotensive phase) and was
suppressed during phase IV (blood pressure overshoot), and 3) nerve activity
increased in response to held expiration.
Tracer calculations. Rates of glucose appearance (Ra), endogenous glucose
production (EGP), and glucose utilization were calculated according to the
methods of Wall et al. (19). EGP was calculated by determining the total Ra
(this comprises EGP and any exogenous glucose infused to maintain the
desired hypoglycemia) and subtracting it from the amount of exogenous
glucose infused. It is now recognized that this approach is not fully quantita-
tive because underestimates of total Ra and rate of glucose disposal (Rd) can
be obtained. The use of a highly puriﬁed tracer and taking measurements
under steady-state conditions (i.e., constant speciﬁc activity) in the presence
of low glucose ﬂux eliminates most, if not all, of the problems. In addition, to
maintain a constant speciﬁc activity, isotope delivery was increased commen-
surate with increases in exogenous glucose infusion. During these studies,
only glucose ﬂux results from the steady-state basal and the ﬁnal 30-min
periods of the hypoglycemic clamps are reported.
Analytical methods. Plasma glucose concentrations were measured in
triplicate using the glucose oxidase method with a glucose analyzer (Beck-
man, Fullerton, CA). Glucagon was measured by radioimmunoassay (RIA)
with an interassay coefﬁcient of variation (CV) of 12% (20). Insulin was
measured as previously described (21) with an interassay CV of 9%. Cat-
echolamines were determined by HPLC (22) with an interassay of 12% for
epinephrine and 8% for norepinephrine. Cortisol was assayed using the
Clinical Assays Gamma Coat RIA kit with an interassay CV of 6%. Growth
hormone was determined by RIA (23) with a CV of 8.6%. Pancreatic polypep-
tide was measured by RIA using the method of Hagopian et al. (24) with an
interassay CV of 8%. Lactate, glycerol, alanine, and -hydroxybutyrate were
measured in deproteinized whole blood using the method of Lloyd et al. (25).
Nonesteriﬁed fatty acids (NEFAs) were measured using the WAKO kit
adopted for use on a centrifugal analyzer (26). Fluoxetine and norﬂuoxetine
were determined by gas chromatography with electron capture detection
based on a modiﬁcation described by Torok-Both et al. (27).
Blood for hormones and intermediary metabolites was drawn twice during
the control period and every 15 min during the experimental period. Cardio-
vascular parameters (pulse, systolic, diastolic, and mean arterial pressure)
were measured noninvasively by a Dinamap (Critikon, Tampa, FL) every 10
min throughout each study starting at 80 min.
Hypoglycemic symptoms were quantiﬁed using a previously validated
semiquantitative questionnaire (28). Each individual was asked to rate his/her
experience of the symptoms twice during the control period and every 15 min
during experimental periods. Symptoms measured included sweat, tremor/
shaking, feeling hot, thirsty/dry mouth, agitation/irritability, palpitations,
feeling tired/fatigued, confusion, dizziness, difﬁculty thinking, blurriness of
vision, and sleepiness. The ratings of the ﬁrst six symptoms were summed to
get the autonomic score, whereas the ratings from the last six symptoms
provide a neuroglycopenic symptom score.
Statistical analysis. Data are expressed as means  SE and were analyzed
using standard, parametric, and one- and two-way ANOVA and with repeated
measures where appropriate (SigmaStat; SPSS Science, Chicago, IL). Tukey’s
post hoc analysis was used to delineate statistical signiﬁcance across time
within each group and for each group compared with the control group. A P
value of 0.05 was accepted as statistically signiﬁcant. The baseline and ﬁnal
30 min of hypoglycemia were compared for most parameters because
steady-state glucose levels, insulin levels, and glucose infusion rates were
achieved by this time.
RESULTS
Glucose, insulin, and ﬂuoxetine levels. Basal plasma
glucose levels were 6.3  0.3 and 5.6  0.2 mmol/l in the
clamps before ﬂuoxetine and before placebo. Basal glu-
cose levels were similar (6.1  0.3 and 5.5  0.3 mmol/l)
after 6 weeks of ﬂuoxetine or placebo. Plasma glucose
levels reached steady state by 30 min, and equivalent
hypoglycemia (2.8  0.1 mmol/l) was maintained during all
clamp procedures (Fig. 1). Basal and steady-state insulin
levels for both ﬂuoxetine and placebo groups were similar
during studies before the clamp (ﬂuoxetine, 120  18 and
660  24 pmol/l, and placebo, 126  30 and 648  54
pmol/l) and after clamp (ﬂuoxetine 120  18 and 630  42
pmol/l, and placebo, 144  30 and 667  36 pmol/l) (Fig.
2). A1C levels were unchanged during ﬂuoxetine (7.0  0.3
to 6.8  0.3%) and placebo (6.9  0.3 to 6.9  0.3%)
administration. Similarly, weight was constant during both
ﬂuoxetine (74.2  13 to 73  714.3 kg) and placebo
(77.5  9 to 77.4  9 kg) administration. Mean ﬂuoxetine
ANS COUNTERREGULATORY RESPONSES TO HYPOGLYCEMIA
3316 DIABETES, VOL. 57, DECEMBER 2008and norﬂuoxetine levels at the end of the study were
274.13  45 and 188.38  34 ng/ml, respectively, in the
SSRI group and were undetectable in the placebo group.
Neuroendocrine counterregulatory hormones. Epi-
nephrine responses were signiﬁcantly higher (P  0.05)
during the ﬁnal 30 min of hypoglycemia after ﬂuoxetine
(5,436  808 pmol/l) compared with before treatment
(3,815  841 pmol/l) and after placebo (3,198  791
pmol/l) hypoglycemic clamp. Epinephrine responses were
similar during the ﬁnal 30 min of the hypoglycemic clamps
before and after placebo (Fig. 2).
Norepinephrine responses were signiﬁcantly higher
(P  0.05) during the ﬁnal 30 min of after ﬂuoxetine (2.3 
0.3 nmol/l) compared with before treatment (1.7  0.2
nmol/l) and after placebo (1.6  0.2 nmol/l). Norepineph-
rine responses were similar during the ﬁnal 30 min of
hypoglycemia during the studies before and after placebo
(Fig. 2).
Cortisol levels were increased (P  0.05) in the after-
ﬂuoxetine versus the after-placebo groups (800  55 vs.
635  83 nmol/l). Cortisol levels remained unchanged
during placebo administration.
Peak pancreatic polypeptide levels during hypoglyce-
mia were practically unchanged (135  37 vs. 138 
27 nmol/l) after ﬂuoxetine administration compared
with values before treatment, respectively. Pancreatic
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FIG. 1. Plasma glucose (A) and insulin (B) concentrations (means  SE) during hypoglycemic clamp studies in 18 individuals (14 men/4 women)
with type 1 diabetes before and after 6 weeks of ﬂuoxetine or placebo administration. pre-SSRI, E; post-SSRI, f; pre-placebo, ‚; post-placebo,  .
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FIG. 2. Mean plasma epinephrine (A), cortisol (B), and norepinephrine (C) levels (means  SE) during the basal period and the ﬁnal 30 min of
hypoglycemic clamp studies in 18 individuals (14 men/four women) with type 1 diabetes before and after 6 weeks of ﬂuoxetine or placebo
administration. *Plasma epinephrine, norepinephrine, and cortisol levels are signiﬁcantly increased (P < 0.05) following ﬂuoxetine. pre-SSRI, E;
post-SSRI, f; pre-placebo, ‚; post-placebo,  .
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group after placebo (115  35 nmol/l) versus before
placebo (121  26 nmol/l) during the ﬁnal 30 min of
hypoglycemia (Fig. 3).
Glucagon responses were similar during hypoglycemia
in all groups (before/after ﬂuoxetine and before/after
placebo) (Fig. 3). Fluoxetine and placebo had similar
effects on growth hormone responses during hypoglyce-
mia. Growth hormone levels during the studies before and
after ﬂuoxetine were 41  7 vs. 36  6 ng/l, respectively,
and were 41  10 vs. 34  7 ng/l for the before- and after-
placebo groups, respectively (Fig. 3).
MSNA. MSNA increased by a signiﬁcantly greater
amount (P  0.05) during hypoglycemia after ﬂuoxetine
(16  3 bursts/min) versus both after placebo (10  2
bursts/min) and before ﬂuoxetine (5  2 bursts/min).
There were no differences in the after-placebo versus
before-placebo responses (Fig. 4).
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FIG. 4. MSNA (A) and total symptom (B) responses during the ﬁnal 30 min of hypoglycemic clamp studies in 18 individuals (14 men/4 women)
with type 1 diabetes before and after 6 weeks of ﬂuoxetine or placebo administration. Data are means  SE. *MSNA responses are signiﬁcantly
increased (P < 0.05) following ﬂuoxetine.
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FIG. 3. Mean plasma pancreatic polypeptide (A), glucagon (B), and growth hormone (C) levels (means  SE) during the basal period and the ﬁnal
30 min of hypoglycemic clamp studies in 18 individuals (14 men/four women) with type 1 diabetes before and after 6 weeks of ﬂuoxetine or
placebo administration.
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tions per minute per milligram) was in a steady state
during the basal period and the ﬁnal 30 min of all hyper-
insulinemic-hypoglycemic clamps (Table 1).
EGP after ﬂuoxetine (11  1.1 mol  kg
1  min
1) was
signiﬁcantly increased (P  0.05) during the ﬁnal 30 min of
hypoglycemia compared with before ﬂuoxetine (5.1  1.1
mol  kg
1  min
1), before placebo (2.2  1.6 mol  kg
1
 min
1), and after placebo (5.0  2.2 mol  kg
1  min
1).
Glucose infusion rates were 14.3  6.1and 8.9  3.9 mol
 kg
1  min
1 after placebo and after ﬂuoxetine, respec-
tively. Glucose Rds during the ﬁnal 30 min of hypoglyce-
mia were 19  2.8 and 19.8  3.3 after placebo and after
ﬂuoxetine, respectively (Fig. 5).
Intermediary metabolism. Baseline glycerol, lactate,
-hydroxybutyrate, NEFA, and alanine levels were similar
among groups (Table 2). Glycerol levels were signiﬁcantly
greater (P  0.05) after ﬂuoxetine (115  18 mol/l)
compared with after placebo (83  16 mol/l) or before
ﬂuoxetine (73  5 mol/l). There was no difference in the
increase of glycerol in the studies before and after placebo
(Table 2).
There was an increase in NEFA levels during hypogly-
cemia after ﬂuoxetine (182  64 mol/l) compared with
after placebo (91  25 mol/l) and before ﬂuoxetine (93 
24 mol/l) (P  0.05) studies. There was no difference in
the increase of NEFA levels during hypoglycemia in the
studies before and after placebo. Blood lactate, alanine,
and -hydroxybutyrate levels were similar during the four
series of hypoglycemic clamps and were unaffected by
ﬂuoxetine or placebo administration (Table 2).
Cardiovascular parameters. Basal heart rate and blood
pressure were not different after a 6-week administration
of ﬂuoxetine. Heart rate was signiﬁcantly higher (P  0.05)
during the ﬁnal 30 min of groups after ﬂuoxetine com-
pared with before ﬂuoxetine and after placebo (80  4 vs.
74  5 and 69  5 bpm, respectively). Heart rate was
similar in the control group (after placebo 69  5 bpm vs.
before placebo, 67  8 bpm). Systolic blood pressure was
signiﬁcantly increased during hypoglycemia in the group
after ﬂuoxetine versus the before-ﬂuoxetine and after-
placebo groups (127  4 vs. 113  3 and 115  6 mmHg,
respectively; P  0.05). There were no differences in
systolic blood pressure in the placebo control group (after
placebo 115  6 mmHg vs. before placebo 119  5 mmHg).
Diastolic blood pressure was also increased after ﬂuox-
etine (P  0.05) compared with after placebo and before
ﬂuoxetine (67  2 vs. 61  3 and 61  1 mmHg,
respectively; Table 3).
Symptom response. There were no differences in total
symptom scores in the experimental group when com-
pared with groups before ﬂuoxetine or after placebo.
Similarly, no signiﬁcant differences occurred in the control
group after placebo compared with the clamp study before
placebo (Fig. 4). Both autonomic and neuroglycopenic
symptoms scores were similar during hypoglycemia be-
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FIG. 5. Glucose kinetics during the basal period and the ﬁnal 30 min of hypoglycemic clamp studies in 18 individuals (14 men/4 women) with type
1 diabetes before and after 6 weeks of ﬂuoxetine or placebo administration. Data are means  SE. *EGP is signiﬁcantly increased (P < 0.05)
following ﬂuoxetine administration.
TABLE 1
Glucose speciﬁc activity during the basal period and the ﬁnal 30 min of hyperinsulinemic-hypoglycemic clamps in subjects with
type 1 diabetes before and after 6 weeks of ﬂuoxetine or placebo administration
Glucose speciﬁc activity (dpm/mmol)
20 min 10 min 0 min 90 min 105 min 120 min
Before ﬂuoxetine 364  22 341  25 367  18 273  22 289  13 276  12
After ﬂuoxetine 334  42 353  33 359  33 262  22 260  20 247  20
Before placebo 326  18 334  24 338  19 271  22 263  17 259  19
After placebo 365  24 369  22 376  24 300  20 289  18 272  18
Data are means  SE.
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toms before ﬂuoxetine were 23  4 vs. 19  4 after
ﬂuoxetine; neuroglycopenic scores were 19  4 before
ﬂuoxetine and 20  4 after ﬂuoxetine).
DISCUSSION
This study has determined the effects of 6-week adminis-
tration of the SSRI ﬂuoxetine on counterregulatory re-
sponses to hypoglycemia in nondepressed patients with
type 1 diabetes. Our results demonstrate that a period of 6
weeks of high-dose ﬂuoxetine signiﬁcantly increases sym-
pathetic nervous system, HPA, and metabolic (EGP and
lipolysis) counterregulatory responses in patients with
long-duration type 1 diabetes.
Hypoglycemia remains the major barrier to even near
normalization of glucose in patients with type 1 diabetes.
We have recently reported the beneﬁcial effects of 6
weeks’ ﬂuoxetine administration on amplifying counter-
regulatory mechanisms during hypoglycemia in nondia-
betic individuals (9). In this present study, we have tested
the hypothesis that 6 weeks’ administration of ﬂuoxetine
will enhance counterregulatory responses during hypogly-
cemia in type 1 diabetes. Similar to studies in nondiabetic
humans, this study has determined that ﬂuoxetine can
have marked effects in amplifying catecholamine re-
sponses and muscle sympathetic nervous activity during
hypoglycemia. The increased sympathetic nervous system
(SNS) activity also had signiﬁcant effects on enhancing the
key counterregulatory metabolic mechanisms of EGP and
lipolysis.
In longer duration type 1 diabetes patients, epinephrine
becomes the critical counterregulatory hormone in the
defense against acute hypoglycemia. This is due to the fact
that with increasing disease duration, the glucagon re-
sponse to hypoglycemia is lost in type 1 diabetes (29).
Unfortunately, in type 1 diabetic patients with repeated
episodes of hypoglycemia and intensive glucose control,
the epinephrine response to hypoglycemia is signiﬁcantly
reduced (30). The combination of absent glucagon and
severely blunted epinephrine responses consequently re-
sults in a signiﬁcant magniﬁcation of the risk for severe
hypoglycemia (30). Perhaps the most notable ﬁnding from
the present study was the striking increase in epinephrine
responses during hypoglycemia following ﬂuoxetine. De-
spite equivalent insulin and glucose levels during the
hypoglycemic clamps, ﬂuoxetine resulted in a 90% in-
crease in epinephrine levels. In fact, ﬂuoxetine increased
the response of epinephrine to levels even higher than
previously observed in nondiabetic individuals during sim-
ilar conditions of hypoglycemia (31). The increased SNS
response following ﬂuoxetine also resulted in a marked
increase in EGP and lipolysis. As can be observed from the
placebo studies, EGP is typically suppressed during hypo-
glycemia in type 1 diabetes. Thus, the ampliﬁed (doubled)
EGP response following ﬂuoxetine represents a poten-
tially important defense against hypoglycemia in type 1
diabetes. The increased lipolytic response following ﬂuox-
etine would also be expected to contribute to the elevated
rates of EGP. Both glycerol, an important gluconeogenic
precursor during hypoglycemia (32), and NEFA, a signiﬁ-
cant provider of energy for gluconeogenesis (32), were
signiﬁcantly increased. Rates of glucose uptake were
unchanged during the series of hypoglycemic clamps.
Previous studies have demonstrated that the dose-
response effects of epinephrine to inhibit glucose uptake
are relatively ﬂat (33,34) in association with increasing the
concentrations of the catecholamines from 600 to 1,000
pg/ml, producing limited actions. Similar to the ﬁndings in
healthy humans, ﬂuoxetine resulted in an increased re-
sponse of cortisol during hypoglycemia. This also demon-
TABLE 2
Plasma glycerol, lactate, -hydroxybutyrate, NEFA, and alanine
levels during the basal period and the ﬁnal 30 min of hyperinsu-
linemic-hypoglycemic clamp studies in type 1 diabetes before
and after 6 weeks of ﬂuoxetine or placebo administration
Basal period Final 30 min
Glycerol (mol/l)
Before treatment 58  76 5  8
After ﬂuoxetine 95  25 110  21*
Before treatment 67  15 74  15
After placebo 73  11 80  17
Lactate (mmol/l)
Before treatment 0.4  0.04 0.75  0.09
After ﬂuoxetine 0.3  0.02 0.83  0.15
Before treatment 0.4  0.04 0.75  0.09
After placebo 0.4  0.05 0.84  0.00
-Hydroxybutyrate (mol/l)
Before treatment 0.099  0.089 0.05  0.03
After ﬂuoxetine 0.046  0.026 0.02  0.01
Before treatment 0.07  0.004 0.019  0.002
After placebo 0.07  0.005 0.02  0.01
NEFA (mol/l)
Before treatment 149  38 93  24
After ﬂuoxetine 165  41 182  64*
Before treatment 131  34 86  22
After placebo 212  37 91  24
Alanine (mol/l)
Before treatment 0.23  0.02 0.22  0.02
After ﬂuoxetine 0.21  0.02 0.21  0.03
Before treatment 0.21  0.02 0.20  0.02
After placebo 0.24  0.03 0.22  0.02
Data are means  SE. *Signiﬁcantly increased responses during ﬁnal
30 min of hypoglycemia after 6 weeks of ﬂuoxetine administration
(P  0.05).
TABLE 3
Cardiovascular responses during hyperinsulinemic-hypoglyce-
mic clamp studies in type 1 diabetes before and after 6 weeks of
ﬂuoxetine or placebo administration
Basal
period
Final 30
min
Heart rate (beats/min)
Before ﬂuoxetine 69  47 4  5
After ﬂuoxetine 69  48 0  4*
Before placebo 67  56 7  8
After placebo 65  56 9  5
Systolic blood pressure (mmHg)
Before ﬂuoxetine 107  3 113  3
After ﬂuoxetine 115  7 127  4*
Before placebo 110  3 119  5
After placebo 110  4 115  6
Diastolic blood pressure (mmHg)
Before ﬂuoxetine 66  16 1  1
After ﬂuoxetine 68  36 7  2*
Before placebo 67  36 3  3
After placebo 65  36 1  3
Data are means  SE. *Signiﬁcantly increased responses during ﬁnal
30 min of hypoglycemia after 6 weeks of ﬂuoxetine administration
(P  0.05).
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multiple neural pathways within the central nervous sys-
tem (7).
Accompanying the ampliﬁed SNS responses were signif-
icant increases in blood pressure and heart rate during
hypoglycemia following ﬂuoxetine. Somewhat surpris-
ingly, there was not an increase in symptom scores despite
the signiﬁcant increases in central ANS drive and the
respective target organ responses (i.e., liver, adipose tis-
sue, and heart) following ﬂuoxetine. This apparent disso-
ciation between neutral symptom responses and increases
in other components of the sympathetic nervous system
following ﬂuoxetine was also clearly demonstrated in the
previous study with nondiabetic individuals (9). These
data further suggest that serotonergic pathways are in-
volved in the generation of symptom responses during
hypoglycemia. Recent work in humans has demonstrated
that hippocampal and thalamic regions of the brain are
activated during hypoglycemia (35). These areas are in-
volved in mood and function known to be affected by
SSRIs (36). We therefore hypothesize that ﬂuoxetine ex-
erted a relatively restraining effect on symptom generation
while stimulating neurohumoral and cardiovascular sym-
pathetic tone during hypoglycemia. Similar to our ﬁndings
in nondiabetic individuals, despite the increased sympa-
thetic nervous system drive and elevated epinephrine
levels, ﬂuoxetine had no effects on amplifying glucagon
responses during hypoglycemia (9). This would add sup-
port to the hypothesis that there is an inherent B-cell
defect restricting glucagon release during hypoglycemia in
type 1 diabetes rather than simply just a loss of ANS input
into the -cells (37).
Another point that should be noted is that ﬂuoxetine
only ampliﬁed counterregulatory responses during hypo-
glycemia and did not increase basal homeostatic mecha-
nisms. Thus, there were no differences in baseline
cardiovascular, metabolic, and neuroendocrine parame-
ters following ﬂuoxetine or placebo. The lack of chronic
effects of an SSRI to increase basal neuroendocrine activ-
ity before hypoglycemia was also reported by Sanders et
al. (10) in their recent study using sertraline in nondiabetic
conscious rats. We also found that chronic administration
of the SSRI ﬂuoxetine in nondiabetic individuals had no
effects on increasing basal cardiovascular, ANS, and met-
abolic function. However, basal plasma cortisol (but not
glucagon and growth hormone) was increased by ﬂuox-
etine in nondiabetic individuals.
Data are accumulating regarding possible mechanisms
for SSRI enhancement of ANS and HPA axis responses
during hypoglycemia. Activation of a number of serotoner-
gic receptors (5HT1A, 5HT1C, 5HT2, and 5HT3) has been
demonstrated to increase sympathetic nervous system
outﬂow (5,6,38,39). Additionally, both systemic and cen-
tral administration of SSRIs have speciﬁcally increased
adrenal catecholamine and epinephrine release (7,8). Two
recent studies have also demonstrated that chronic admin-
istration of different SSRIs can amplify counterregulatory
responses during hypoglycemia in both healthy humans
and conscious rats (9,10). The ﬁndings of increased corti-
sol and catecholamines cannot determine whether the
SSRI was being sensed at central (i.e., brain), peripheral
(i.e., adrenal gland), or even both sites to augment coun-
terregulatory responses. However, the ﬁnding that MSNA
was increased in the present study certainly indicates that
central sensing and action of the SSRI were occurring. The
effects of SSRIs on HPA responses during stress appear to
be more complex. We have found that ﬂuoxetine can
increase plasma cortisol responses during hypoglycemia
in both healthy and type 1 diabetes humans. Durand et al.
(40) have also demonstrated that ﬂuoxetine can amplify
corticosteroid responses to stress in conscious rats. How-
ever, Sanders et al. (10), studying a different SSRI (sertra-
line) and species of rat (Spraque-Dawley), found no
ampliﬁcation of HPA axis responses during hypoglycemia.
Thus, the physiological effects of SSRI may be different
depending on the speciﬁc agent and experimental model
under investigation.
The present study has provided an evaluation of the
effects of ﬂuoxetine on physiological responses during
hypoglycemia in a group of metabolically well-controlled
type 1 diabetic patients. These individuals typically have
the highest prevalence of hypoglycemia and might be
expected to beneﬁt most from strategies aimed at improv-
ing ANS responses. Six-week administration of high-dose
ﬂuoxetine had marked effects in amplifying epinephrine
and metabolic counterregulatory responses. However,
the dose of ﬂuoxetine used in this study is higher than the
average dose of the drug used in clinical practice, 33
mg/day (41). Fluoxetine was increased to the highest
clinically approved dose of the drug because we wanted to
ensure that the largest experimental signal was generated
in these initial studies. Additionally, the subjects enrolled
in our study were not depressed and did not have any
major psychopathology. Thus, we cannot determine
whether similar results would be obtained in depressed
individuals. In addition, we did not formally assess
whether ﬂuoxetine would have any effects on cognitive
function during hypoglycemia. This is an important clini-
cal consideration and deserves further study. Overall,
ﬂuoxetine was well tolerated. Body weight and A1C were
no different in the placebo or ﬂuoxetine groups. Rates of
hypoglycemia (albeit anecdotally reported by the patients)
appeared to be unchanged (n  3), improved (n  3), or
relatively improved (n  2) (i.e., unchanged frequency of
hypoglycemia with improvement in A1C of 0.8%). There-
fore, we cannot determine whether ﬂuoxetine increased
sympathoadrenal responses by reducing episodes of ante-
cedent hypoglycemia and/or by directly stimulating ANS
responses during any given episode of hypoglycemia.
Fluoxetine administration was started at 20 mg and
increased in a stepwise fashion to 80 mg in an attempt to
limit side effects of the drug. However, two subjects
receiving ﬂuoxetine withdrew early from the study.
Both of these subjects were only receiving 20 mg of the
drug and reported nonspeciﬁc side effects. Interestingly,
the higher doses of the drug (60–80 mg/day) were very
well tolerated, with no reports of unpleasant side ef-
fects. Thus, in the present study (and our previous study
in nondiabetic individuals), the side effects with ﬂuox-
etine appeared early, dissipated after continued use, and
were not dose related.
In summary, this study has demonstrated that 6 weeks’
administration of ﬂuoxetine can markedly increase key
sympathetic nervous system (epinephrine, norepineph-
rine, and muscle sympathetic nervous system), metabolic
(EGP and lipolysis), and cardiovascular counterregulatory
responses during clamped moderate (2.8 mmol/l) hypogly-
cemia in type 1 diabetes. The study also demonstrates that
serotonergic mechanisms can play a signiﬁcant role in
regulating ANS and HPA physiological responses during
hypoglycemia in type 1 diabetic individuals. In conclusion,
the present results have provided novel ﬁndings demon-
V.J. BRISCOE AND ASSOCIATES
DIABETES, VOL. 57, DECEMBER 2008 3321strating that under the conditions of the present study,
SSRIs (speciﬁcally ﬂuoxetine) may provide beneﬁcial ad-
junct effects in amplifying epinephrine levels during hypo-
glycemia in type 1 diabetic individuals.
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